BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
COSENTYX (secukinumab) by Novartis is interleukin-17a antagonists [moa]. Approved for interleukin-17a antagonist [epc]. First approved in 2023.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSENTYX (secukinumab) is a monoclonal antibody that selectively blocks interleukin-17A (IL-17A), a key cytokine driving inflammatory and autoimmune diseases. It is used to treat conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other IL-17A-mediated disorders. By inhibiting IL-17A signaling, secukinumab reduces inflammation and improves clinical outcomes across multiple indication areas.
Growth
COSENTYX is in active growth phase with moderate competitive pressure (30%), indicating expanding team headcount and investment in commercial infrastructure.
Mechanism of Action
Interleukin-17A Antagonists
Pharmacologic Class:
Interleukin-17A Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Started Jun 2026
36 enrolled
Hidradenitis Suppurativa (HS)
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
Started Jun 2026
186 enrolled
PsoriasisPlaque PsoriasisModerate-to-severe Plaque Psoriasis+1 more
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Started May 2026
34 enrolled
Hidradenitis Suppurativa
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Started Dec 2025
76 enrolled
Hidradenitis SuppurativaPediatric Plaque PsoriasisJuvenile Idiopathic Arthritis
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Started Dec 2025
250 enrolled
Hidradenitis Suppurativa
Worked on COSENTYX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.